i-Pharm Consulting

Yesterday, we looked at a new survey in the biopharma industry that looked at the increasing importance of sustainability. Now, we wanted to look at some challenges that are facing the incorporation of sustainable practices. 🔎 Weak collaboration across the value chain and difficulties in accurately measuring the financial impact of sustainability efforts are major obstacles. 64% of survey respondents believe that failing to meet sustainability targets poses a critical threat to their business. Moreover, 69% of survey participants report that collaboration on sustainability strategies is insufficient, and 76% struggle with accurately forecasting the financial impact of these initiatives. These findings underscore the urgent need for the industry to enhance its collaborative efforts and develop more reliable metrics to measure progress. 🌱 ___________ How do you see sustainability impacting the future of the biopharma industry? Comment your thoughts below! #sustainability #biopharma #iPharm

Sustainability is more than just a goal, it's becoming a defining factor in the biopharma industry. 🌍 A recent comprehensive survey of over 800 biopharma executives highlights the growing importance of sustainability, with 62% of companies identifying it as a top priority. The benefits are clear: improved brand reputation, increased profits, higher share prices, and enhanced talent attraction. Executives like David Butler of Hongene Biotech emphasise the strategic and financial sense of pursuing sustainable practices, citing long-term cost savings as a key driver. The potential rewards for companies, and for the planet are immense. ______________ Do you see any challenges that could come with these opportunities? Comment your thoughts below! #biopharma #iPharm #sustainability

Last week, we looked at cresomycin, a new synthetic antibiotic developed by researchers at the University of Illinois Chicago and Harvard University. We asked for your opinions on how do you think synthetic antibiotics like cresomycin will impact the future of medicine. 💊 The results are in, 48% of you thought it was too early to tell, and 26% think it is useful, but not a game changer. This cautious approach is telling of our industry, where precaution is essential for steady growth. Leave your thoughts on these results in the comments! 💬 #iPharm #antibiotic #drugdevelopment

Yesterday, we posted about BiologIC Technologies' innovative space medicine project. ✨ With a £65m boost from the UK Space Agency, the potential to improve healthcare, speed up aging research, and develop sustainable production methods in space could change how we approach major challenges on Earth. We’d love to hear what you think about this news. Vote in the poll below and leave your thoughts in the comments. 💬 #spaceinnovation #biotech #iPharm

BiologIC Technologies in Cambridgeshire is set to revolutionise space medicine! With £65m from the UK Space Agency, they’re adapting their advanced system for manufacturing vaccines and gene therapies to function in microgravity aboard the ISS. This could change healthcare, speeding up aging research, enabling organ growth, and fostering sustainable material production. 🚀 As "Space Race 2.0" unfolds, the focus is on sustainability, and BiologIC’s work is key to making life beyond Earth possible. This project highlights the UK's strength in space science with far-reaching benefits. ___________ How do you feel about the potential of space-based research to transform healthcare and sustainability on Earth? #spaceinnovation #biotech #iPharm

Last week, we shared news about cresomycin, a new synthetic antibiotic developed by researchers at the University of Illinois Chicago and Harvard University. This promising compound has shown great potential in early tests against multidrug-resistant bacteria, including those responsible for healthcare-acquired infections. 🦠 Now, we want to hear what you think! How do you think synthetic antibiotics like cresomycin will impact the future of medicine? 🔘 A major breakthrough in fighting drug-resistant bacteria 🔘 Useful but won't be a game-changer 🔘 Too early to tell 🔘 Unsure about the impact Vote in the poll below and leave your thoughts in the comments! 💬 #iPharm #antibiotic #drugdevelopment

Last week, we looked at the latest industry news surrounding ventilator recalls and what this means for the future of the life sciences industry. 🫁 We asked for your opinions on the role of regulatory bodies in preemptively identifying potential issues while supporting innovation. The results are in, and with 44% of you voting for improved culture of quality as the key driver for improving the reliability of medical devices, it is clear that a precedent must be set across the industry with expectations and standards to be met. ____________________ Read more on the topic here: 🔗 https://lnkd.in/eh4d_rDK #iPharm #ventilatorrecalls #lifesciences

Have you caught up on the latest edition of i-Pharm Insight yet? We took a deep dive into a topic that's crucial for the pharmaceutical and medical device industry: ventilator recalls. 🗞️ This month, we take a comprehensive look at: 🔍 The root causes behind these recalls 📜 Regulatory responses and actions taken 🏭 Steps manufacturers are taking to enhance product safety Discover how these recalls are driving significant improvements and ensuring the highest standards of care across the medical device sector. Click the link below to read the full newsletter! 🔗 https://lnkd.in/eriiY_8w #iPharmInsights #iPharm #ventilatorrecalls

A new synthetic antibiotic, cresomycin, has shown promising results in early tests against flesh-eating bacteria and other multidrug-resistant pathogens. 💊 Researchers from the University of Illinois Chicago and Harvard University discovered that cresomycin is effective in killing various resistant bacteria strains in cell cultures and mice. This antibiotic works by binding tightly to the bacterial ribosome, disrupting protein synthesis even in bacteria that have developed resistance mechanisms. In tests, cresomycin effectively killed multidrug-resistant bacteria, including those responsible for many healthcare-acquired infections. In mouse models, it significantly improved survival rates and reduced bacterial loads compared to control groups. The research team, supported by a $1.2 million grant from CARB-X, plans to continue developing the compound for potential clinical use. We look forward to seeing how this development in our industry plays out! 💡 #drugdevelopment #iPharm #antibiotic

This week, we have been looking at the latest industry news surrounding ventilator recalls and what this means for the future of the life sciences industry. 🤔 It has raised essential questions about the role of regulatory bodies in preemptively identifying potential issues while supporting innovation. ____________________ Now, we want to hear your thoughts! Vote in the poll below and let us know what you think is most important moving forward. 🗳️ #iPharm #ventilatorrecalls #lifesciences